Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization

American Journal of Psychiatry

Volumn 167, Issue 8, 2010, Pages 987-993

  Foti, Daniel J ^a   Kotov, Roman ^a   Guey, Lin T ^a   Bromet, Evelyn J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CANNABIS ADDICTION; DISEASE COURSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SOCIOECONOMICS; SURVIVAL; SYMPTOM;

ADOLESCENT; ADULT; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MARIJUANA ABUSE; MIDDLE AGED; NEW YORK; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 77955355100     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.09020189     Document Type: Article

References (40)

1. Green B, Young R, Kavanagh D: Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187:306-313 (Pubitemid 41442380)
2. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS: Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004; 291:2114-2121
3. Arseneault L, Cannon M, Witton J, Murray RM: Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184:110-117 (Pubitemid 38186851)
4. Smit F, Bolier L, Cuijpers P: Cannabis use and the risk of later schizophrenia: a review. Addiction 2004; 99:425-430 (Pubitemid 38496658)
5. Hall W, Degenhardt L: Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008; 7:68-71
6. Hall W, Degenhardt L: Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust NZ J Psychiatry 2000; 34:26-34 (Pubitemid 34692842)
7. Hambrecht M, Hafner H: Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust NZ J Psychiatry 2000; 34:468-475 (Pubitemid 30389416)
8. Veen ND, Selten J-P, van der Tweel I, Feller WG, Hoek HW, Kahn RS: Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004; 161:501-506 (Pubitemid 38326105)
9. Degenhardt L, Hall W, Lynskey M: Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71:37-48 (Pubitemid 36734857)
10. DeLisi LE: The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry 2008; 21:140-150
11. Dixon L, Haas G, Weiden P, Sweeney J, Frances A: Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull 1990; 16:69-79 (Pubitemid 20110376)
12. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P: Cannabis and schizophrenia: impact on onset, course, psychopathology, and outcomes. Eur Arch Psychiatry Clin Neurosci 2002; 252:86-92 (Pubitemid 36056682)
13. Peralta V, Cuesta MJ: Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992; 85:127-130
14. Negrete JC, Knapp WP, Douglas DE, Smith WB: Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med 1986; 16:515-520
15. Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008; 193:357-363
16. Caspari D: Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999; 249:45-49 (Pubitemid 29366776)
17. Arias Horcajadas F, Sánchez Romero S, Padín Calo JJ: Influencia del consumo de drogas en las manifestaciones clínicas de la esquizofrenia (Relevance of drug use in clinical manifestations of schizophrenia). Actas Esp Psiquiatr 2002; 30:65-73
18. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM: Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005; 20:349-353 (Pubitemid 40978562)
19. Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, McKay D: The temporal dynamics of relationships between cannabis, psychosis, and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 2007; 37:927-934 (Pubitemid 46993593)
20. Degenhardt L, Hall W, Lynskey M: Exploring the association between cannabis use and depression. Addiction 2003; 98:1493-1504 (Pubitemid 37373847)
21. Arndt S, Tyrrell G, Flaum M, Andreasen NC: Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol Med 1992; 22:379-388
22. Bromet EJ, Schwartz JE, Fennig S, Geller L, Jandorf L, Kovasznay B, Lavelle J, Miller A, Pato C, Ram R, Rich C: The epidemiology of psychosis: the Suffolk County Mental Health Project. Schizophr Bull 1992; 18:243-255
23. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version. New York, New York State Psychiatric Institute, Biometrics Research, 1997
24. Schwartz JE, Fennig S, Tanenberg-Karant M, Carlson G, Craig T, Galambos N, Lavelle J, Bromet EJ: Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry 2000; 57:593-600 (Pubitemid 30349440)
25. National Household Survey on Drug Abuse: Main Findings, 1985. Rockville, Md, National Institute on Drug Abuse, 1988
26. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1983
27. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
28. Grube BS, Bilder RM, Goldman RS: Meta-analysis of symptom factors in schizophrenia. Schizophr Res 1998; 31:113-120
29. Kotov R, Guey LT, Bromet EJ, Schwartz JE: Smoking in schizophrenia: diagnostic specificity, symptom correlates, and illness severity. Schizophr Bull 2010; 36:173-181
30. Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N: Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 2000; 157:60-66
31. Verbeke G, Molenberghs G: Linear Mixed Models for Longitudinal Data. New York, Springer-Verlag, 2000
32. Hu L, Bentler PM: Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Structural Equation Modeling 1999; 6:1-55
33. Schafer JL, Graham JW: Missing data: our view of the state of the art. Psychol Methods 2002; 7:147-177
34. McArdle JJ, Hamagami F: Modeling incomplete longitudinal and cross-sectional data using latent growth structural models. Exp Aging Res 1992; 18:145-166
35. Miller JD: National Survey on Drug Abuse: Main Findings, 1982. Rockville, Md, National Institute on Drug Abuse, 1983
36. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC: Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100:612-618 (Pubitemid 40646286)
37. Hides L, Dawe S, Kavanagh DJ, Young RM: Psychotic symptoms and cannabis relapse in recent-onset psychosis: prospective study. Br J Psychiatry 2006; 189:137-143 (Pubitemid 44231272)
38. Noordsy DL, Green AI: Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003; 5:340-346 (Pubitemid 38899227)
39. Drake RE, Essock SM, Shaner A, Carey KB, Minkoff K, Kola L: Implementing dual diagnosis services for consumers with severe mental illness. Psychiatr Serv 2001; 52:469-476 (Pubitemid 32275306)
40. Tiet QQ, Mausbach B: Treatments for patients with dual diagnosis: a review. Alcohol Clin Exp Res 2007; 31:513-536 (Pubitemid 46434889)